India’s pharma footprint in Iran faces new US pressure

14 January 2026

US President Donald Trump’s recent warning of a 25% tariff on countries trading with Iran introduces fresh uncertainty for India’s economic engagement with the West Asian nation, reports The Pharma Letter’s India correspondent.

The move, framed as part of Washington’s pressure campaign on Tehran, comes at a time when India’s exports to Iran, particularly in pharmaceuticals, have reached record highs.

Pharmaceutical exports surged 70% in 2025, reaching $44.26 million, the highest in five years, according to data from the Department of Commerce.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight



More Features in Pharmaceutical